Objective Response Rate (Part I) baseline to 18 months [clinicaltrials_resource:be21aee856353662fc6b4b214a761e6c]
The primary objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) - IV Large Cell Carcinoma of the Lung with neuroendocrine markers. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable response means did not meet criteria for progressive or partical response. 20% progressive disease.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Objective Response Rate (Part I) baseline to 18 months [clinicaltrials_resource:be21aee856353662fc6b4b214a761e6c]
The primary objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) - IV Large Cell Carcinoma of the Lung with neuroendocrine markers. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable response means did not meet criteria for progressive or partical response. 20% progressive disease.
Bio2RDF identifier
be21aee856353662fc6b4b214a761e6c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:be21aee856353662fc6b4b214a761e6c
measure [clinicaltrials_vocabulary:measure]
Objective Response Rate (Part I)
time frame [clinicaltrials_vocabulary:time-frame]
baseline to 18 months
description
The primary objective is to de ...... nse. 20% progressive disease.
identifier
clinicaltrials_resource:be21aee856353662fc6b4b214a761e6c
title
Objective Response Rate (Part I) baseline to 18 months
@en
type
label
Objective Response Rate (Part ...... 1aee856353662fc6b4b214a761e6c]
@en